• Citer

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

par Peyrin-Biroulet, Laurent;Deltenre, Pierre ;de Suray, Nicolas;Branche, Julien;Sandborn, William J;Colombel, Jean Frédéric
Référence Clinical gastroenterology and hepatology, 6, 6, page (644-653)
Publication Publié, 2008-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
Auteur:	Peyrin-Biroulet, Laurent; Deltenre, Pierre; de Suray, Nicolas; Branche, Julien; Sandborn, William J; Colombel, Jean Frédéric
Informations sur la publication:	Clinical gastroenterology and hepatology, 6, 6, page (644-653)
Statut de publication:	Publié, 2008-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adalimumab
	Antibodies, Monoclonal -- adverse effects -- therapeutic use
	Antibodies, Monoclonal, Humanized
	Certolizumab Pegol
	Crohn Disease -- drug therapy
	Fistula -- drug therapy
	Follow-Up Studies
	Humans
	Immunoglobulin Fab Fragments -- adverse effects -- therapeutic use
	Immunologic Factors -- adverse effects -- therapeutic use
	Infliximab
	Placebos
	Polyethylene Glycols -- adverse effects -- therapeutic use
	Randomized Controlled Trials as Topic
	Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Langue:	Anglais
Identificateurs:	urn:issn:1542-3565
	info:doi/10.1016/j.cgh.2008.03.014
	info:pii/S1542-3565(08)00291-7
	info:pmid/18550004